Compare Enbridge Inc (ENB) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs Tempus AI — how do they compare? Enbridge Inc trades at $46.55 (market cap $102.60B), while Tempus AI trades at $70.04 (market cap $12.77B). The key difference: Enbridge Inc is far larger — about 8× Tempus AI's market cap, and Enbridge Inc pays a 6.1% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enbridge Inc for 91 Days and Tempus AI for 22 Days on average.
| ENB | TEM | |
|---|---|---|
Market Cap | $102.60B | $12.77B |
Volume | 3,673,079 | 8,980,490 |
Sector | Energy | Broad Market / Factor |
52-Week High | $58.04 | $99.28 |
52-Week Low | $45.23 | $41.55 |
Typical Hold Time | 91 Days | 22 Days |
Enterprise Value | $184.87B | $13.40B |
Dividend Yield | 6.1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Enbridge (ENB) trades at $46.54, showing no change in the latest session. The stock exhibits a bearish technical signal with strong selling pressure on moving averages, though RSI levels suggest potential oversold conditions. Fundamentally, the company reported revenue of $65.19 billion in 2025 with a net income margin of 7.34%, while consistently beating EPS estimates in recent quarters. A dividend of $0.97 per share is scheduled for payment on September 1, 2026.
The outlook for ENB is mixed; analyst consensus is a 'Buy' with a price target of $61.63, implying significant upside, but technical indicators and rising debt-to-asset ratios pose risks. Investment opportunity lies in its stable cash flows and dividend yield, while key risks include interest rate sensitivity and execution of its $41 billion project backlog.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
